Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Phase 2

Completed

• Conditions: Plaque Psoriasis
• Interventions: Drug: Halobetasol Proprionate Cream 0.05%; Drug: Halobetasol Proprionate Lotion 0.05%

• Registration Number: NCT01166646
• Lead Sponsor: Therapeutics, Inc.

Brief Summary

The purpose of this study is to determine whether the investigational lotion is an effective treatment of moderate to severe plaque psoriasis in comparison to an approved cream.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-07
• Study First Submitted: 2010-07-19
• Study First Submitted QC: 2010-07-19
• Study First Posted: 2010-07-21
• Primary Completion: 2011-07
• Study Completion: 2011-07
• Disposition First Submitted: 2012-12-05
• Disposition First Submitted QC: 2012-12-05
• Disposition First Posted: 2012-12-07
• Results First Submitted: 2016-03-10
• Status Verified: 2016-04
• Results First Submitted QC: 2016-04-11
• Last Update Submitted: 2016-04-11
• Results First Posted: 2016-05-16
• Last Update Posted: 2016-05-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

• Subjects are male or non-pregnant female; 18 years of age at the time of screening.
• Subjects provide Institutional Review Board (IRB) approved written informed consent for participating in this study.
• Subjects have a clinical diagnosis of stable plaque psoriasis involving a minimum of 20% body surface area and an Overall Disease Severity (ODS) score on the designated treatment area of at least 3 as determined by the evaluating investigator.
• Subjects are willing and able to apply the study medication as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
• Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at the Screening (Part B) and Baseline Visits and agree to use an effective form of birth control for the duration of the study (abstinence, stabilized on oral contraceptives or contraceptive patches for at least three months, implant, injection, IUD, NuvaRing®, condom and spermicidal or diaphragm and spermicidal). Abstinence is an acceptable form of birth control for subjects who are not sexually active. Subjects who become sexually active during the trial must agree to use an effective, non-prohibited form of birth control for the duration of the study.

Exclusion Criteria

• Subjects have spontaneously improving or rapidly deteriorating plaque psoriasis, or have guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.
• Subjects have a physical condition which, in the Investigator's opinion, might impair evaluation of plaque psoriasis, adrenal axis function (e.g., Addison's Disease, Cushing's Syndrome) or which exposes the subject to an unacceptable risk by study participation.
• Subjects have used any phototherapy (including laser), photo-chemotherapy or systemic psoriasis therapy including methotrexate, retinoids, cyclosporine or biologics within 30 days prior to the initiation of study medication treatment.
• Subjects have used systemic corticosteroids (including oral or intramuscular) or topical, inhaled or intranasal corticosteroids within 30 or 14 days, respectively, prior to Part B of the Screening Visit and/or subjects have used systemic or topical corticosteroids between the Screening Visit and the initiation of treatment.
• Subjects have had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to the initiation of treatment or are intending to have such exposure during the study that is thought by the Investigator to likely modify the subject's disease.
• Subjects have used topical psoriatic therapy including tar, anthralin, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to the initiation of study medication treatment.
• Subjects have used emollients/moisturizers on areas to be treated within one day prior to the initiation of study medication treatment.
• Subjects are currently using lithium or plaquenil.
• Subjects are currently using a beta-blocking medication (e.g., propanolol) or angiotensin converting enzyme (ACE) inhibitors at a dose that has not been stabilized, in the opinion of the Investigator.
• Subjects have a history of sensitivity to any of the ingredients in the study medication.
• Subjects are pregnant, nursing or planning a pregnancy during the study period.
• Subjects are currently enrolled in an investigational drug or device study.
• Subjects have received an investigational drug or an investigational device within 30 days prior to screening.
• Subjects have been previously enrolled in this study and treated with the study medication.
• Subjects have irregular sleep schedules or work night shifts (cortisol levels exhibit physiological diurnal variation).
• Subjects have a screening CST with a post 30-minute stimulation cortisol level of ≤ 18 µg/dL.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Halobetasol Proprionate Cream 0.05%	Halobetasol Proprionate Cream 0.05%	Subjects randomized to receive cream
Halobetasol Proprionate Lotion 0.05%	Halobetasol Proprionate Lotion 0.05%	Subjects randomized to receive lotion

Primary Outcome Measures

Name	Time	Method
Adrenal Suppression Potential	After 1-2 weeks dose	Hypothalamic Pituitary-Adrenal (HPA)-Axis responses to Cosyntropin Stimulation Testing (CST) were dichotomized to normal and abnormal. An abnormal HPA Axis response (HPA Suppression) was defined as a 30-minute post-stimulation serum cortisol level of ≤18 μg/dL at the end of treatment.
Pharmacokinetic Properties (Cmax)	Day 8	Comparison of PK results (peak concentration in plasma \[Cmax\]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.
Pharmacokinetic Properties (Tmax)	Day 8	Comparison of PK results (time to peak concentration \[Tmax\]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.
Pharmacokinetic Properties (AUC)	Day 8	Comparison of PK results (area under the curve \[AUC\] from time 0 to infinity) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.

Secondary Outcome Measures

Name	Time	Method
Changes in Disease Severity (Success)	Day 15	Overall disease severity (ODS) will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. ODS evaluations will be dichotomized to "success" and "failure" with success defined as a grade of 1 or 0 at the end of treatment (EOT).
Number of Subjects Whose Signs of Psoriasis Was Designated "Success"	Day 15	Signs of psoriasis including scaling, erythema, and plaque elevation will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. Each of the signs of psoriasis will be dichotomized to a) "success" and "failure" with success defined as a grade of 1 or 0 at the End of Treatment (EOT; i.e., the visit at which psoriasis has cleared \[Day 8 or Day 15\] or end of the assigned treatment period).

Trial Locations

Locations (5)

DermResearch Inc.; 🇺🇸 Austin, Texas, United States

Michigan Center for Skin Care Research (dba Skin Care Research); 🇺🇸 Clinton Township, Michigan, United States

Somerset Skin Centre; 🇺🇸 Troy, Michigan, United States

Dermatology, Laser & Vein Specialists of the Carolinas PLLC; 🇺🇸 Charlotte, North Carolina, United States

Therapeutics Clinical Research; 🇺🇸 San Diego, California, United States